Observations from BIO 2011
The Lacerta Bio team attended the annual BIO Convention in Washington, DC last week. BIO has become one of the key conventions for pharma/biotech business development, and is a "must…
Menu
Dear Pharma, What Went Wrong?
The pharmaceutical industry has benefitted mankind by developing life-saving and life-sustaining drugs. However, recent turmoils have led many to question the value provided by the industry. Matt Herper tackles these complex issues across two blog posts.
Is deal-making becoming more difficult?
The June, 2011 issue of Nature Drug Discovery has a interesting short article based on a survey conducted by our good friends at PharmaVentures. The authors surveyed 180 business development…
Sandwich Shoppe For Sale
We posted in February the news that Pfizer was closing their large R&D facility in Kent, UK. It was with some surprise that we learn that the facility is already…
The SmartCells Story
Bruce Booth from Atlas Ventures has a fascinating story on his blog. We won't steal Bruce's thunder. Instead, we encourage you to read it there first. The gist of the story is…
The Era of the One Man Pharma Band (With Updates)
There is a fascinating discussion taking place over at Derek Lowe's blog today on one-man drug companies: ...some of them are not quite down to one person, but you can…
One man’s junk = another man’s treasure
Today we learn that Rigel has raised $130 million in financing, in part, to develop candidates in rheumatoid arthritis and other areas. But, as reported by Xconomy, the real gem…
The New Marketing Trifecta
Flowtown has a terrific (and large!) graphic entitled "The New Marketing Trifecta." The trifecta refers to the three ways companies should (or could) be marketing their products and services. These are eMail,…
Drug Resistance = Opportunity
Bloomberg has a good round up of several emerging pharmaceutical companies developing antibiotics. As the article notes, Big Pharma has largely moved away from antibiotic development for a number of…
Innovation for Chronic Conditions
There is an excellent editorial in the May issue of Nature Biotechnology entitled Inadequately met needs. In it, the author points out that the US is moving away from innovative,…